Last Updated : April 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis, glucocorticoid induced | Do not list | Complete | ||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis (in women), Severe | Do not list | Complete | ||
| Egrifta | Tesamorelin | Lipodystrophy, HIV-infected patients | Do not reimburse | Complete | ||
| Symdeko | tezacaftor/ivacaftor | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Tezspire | tezepelumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Brilinta | ticagrelor | Prevention of atherothrombotic events with history of myocardial infarction | Reimburse with clinical criteria and/or conditions | Complete | ||
| Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled |
Last Updated : April 18, 2024